Get the Stockscreener App
8.58
1.66%
0.14
After Hours:
8.57
-0.010
-0.12%
Theravance Biopharma Inc stock is traded at $8.58, with a volume of 157.11K.
It is up +1.66% in the last 24 hours and down -13.86% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$8.44
Open:
$8.53
24h Volume:
157.11K
Relative Volume:
0.90
Market Cap:
$417.27M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-9.3261
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-2.28%
1M Performance:
-13.86%
6M Performance:
-13.25%
1Y Performance:
-12.09%
1-Day Range:
$8.41
$8.59
1-Week Range:
$8.35
$8.86
52-Week Range:
$7.44
$10.44
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
8.58 | 417.27M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Barclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Barclays PLC Has $529,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
How To Trade (TBPH) - Stock Traders Daily
Zacks Research Issues Optimistic Estimate for TBPH Earnings - Defense World
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Research Report 2024-2030 Featuring Allergan, Basilea Pharmaceutica, Merck, Pfizer, The Medicines Co, Theravance Biopharma - GlobeNewswire
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs - GlobeNewswire
(TBPH) On The My Stocks Page - Stock Traders Daily
Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) - Yahoo Finance
Franklin Resources Inc. Trims Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Barclays PLC Has $529,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by State Street Corp - MarketBeat
State Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,372 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference - PR Newswire
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? - MSN
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics - The Globe and Mail
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
What is Zacks Research's Estimate for TBPH FY2024 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
(TBPH) Trading Advice - Stock Traders Daily
Theravance Biopharma (STU:0TB) Shares Outstanding (EOP) : 49.17 Mil (As of Sep. 2024) - GuruFocus.com
105,609 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Algert Global LLC - MarketBeat
Trading (TBPH) With Integrated Risk Controls - Stock Traders Daily
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan
Baupost's top Q3 trades include Jazz exit, new Dollar General stake - MSN
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
(TBPH) Investment Report - Stock Traders Daily
Theravance Biopharma Inc (TBPH) Quarterly 10-Q Report - Quartzy
Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada
Earnings call: Theravance Biopharma reports growth in Q3 2024 - Investing.com
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Initiatives - GuruFocus.com
Theravance Biopharma’s Third Quarter 2024 Financial Insights - TipRanks
Theravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimat - GuruFocus.com
Theravance Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For - Simply Wall St
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):